Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07324616 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate EDG-7500 in Adults With Hepatic Impairment
A Phase 1 study of Hepatic Impairment (HI), sponsored by Edgewise Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
- 2
- Study locations
NCT07324616 is a Phase 1 study of Hepatic Impairment (HI) that is actively recruiting participants, run by Edgewise Therapeutics. The registered enrollment target is 32 participants. The trial reports 2 study locations across 1 state.
The verdict
NCT07324616, a Phase 1 study of Hepatic Impairment (HI), is actively recruiting participants, sponsored by Edgewise Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this Phase 1 study is to understand and compare the amount of EDG-7500 in the blood after a single dose in participants with different levels of liver function impairment versus participants with normal liver function. The safety of EDG-7500 in adult participants with different levels of liver function impairment will also be evaluated in this study.
Conditions Studied
Interventions
- DRUG EDG-7500
Study Locations (2)
Florida
- The University of Miami Division of Clinical Pharmacology - Miami
- Orlando Clinical Research Center - Orlando
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2026-01-26 |
| Est. Completion | 2026-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07324616
The ClinicalTrials.gov registry entry for NCT07324616 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Edgewise Therapeutics, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hepatic Impairment (HI) appearing as the primary indexed condition, and to 1 intervention - of which EDG-7500 is the first listed.
NCT07324616 reports 2 study locations spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT07324616 about?
NCT07324616 is a clinical study titled "A Study to Evaluate EDG-7500 in Adults With Hepatic Impairment". The purpose of this Phase 1 study is to understand and compare the amount of EDG-7500 in the blood after a single dose in participants with different levels of liver function impairment versus participants with normal liver function. The safety of EDG-7500 in adult participants with different levels...
What is the current status of trial NCT07324616?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2026-01-26. Estimated completion is 2026-05.
What conditions does trial NCT07324616 study?
This clinical trial studies the following conditions: Hepatic Impairment (HI).
What interventions are being tested in trial NCT07324616?
The interventions under investigation include: EDG-7500 (DRUG).
Who is sponsoring clinical trial NCT07324616?
This trial is sponsored by Edgewise Therapeutics, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07324616 being conducted?
This trial has 2 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatic Impairment (HI)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.